Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and ...
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.